N-(2-氯-6-甲基苯基)-2-[(6-氯-2-甲基-4-嘧啶基)氨基]-5-噻唑甲酰胺 | 302964-08-5

• 物质功能分类: 医药中间体 - 原料药中间体
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-(2-氯-6-甲基苯基)-2-[(6-氯-2-甲基-4-嘧啶基)氨基]-5-噻唑甲酰胺
• 中文别名: N-(2-氯-6-甲基苯基)-2-[(6-氯-2-甲基-4-嘧啶基)氨基]-5-噻唑酰胺；N-(2-氯-6-甲基苯基)-2-[(6-氯-2-甲基-4-嘧啶基)基]-5-噻唑甲酰胺；N-(2-氯-6-甲基苯基/ l)-2-[((6-氯-2-甲基-4-嘧啶/ l)氨基]-5-噻唑甲酰胺；N-(2-氯-6-甲基苯基/ l)-2-[((6-氯-2-甲基-4-嘧啶/ l)氨基] -5-噻唑甲酰胺；N-(2-氯-6-甲基苯基)-2-(6-氯-2-甲基-4-嘧啶基)氨基-5-噻唑甲酰胺；N-(2-氯-6-甲基苯基)-2-((6-氯-2-甲基-4-嘧啶基)氨基)-5-噻唑甲酰胺
• 英文名称: 2-(6-chloro-2-methylpyrimidin-4-ylamino)-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide
• 英文别名: N-(2-chloro-6-methylphenyl)-2-[(6-chloro-2-methyl-4-pyrimidinyl)amino]-5-thiazolecarboxamide；2-(6-chloro-2-methylpyrimidine-4-ylamino)-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide；N-(2-chloro-6-methylphenyl)-2-[(6-chloro-2-methylpyrimidin-4-yl)amino]-1,3-thiazole-5-carboxamide
• CAS: 302964-08-5
• 化学式: C₁₆H₁₃Cl₂N₅OS
• 分子量: 394.284
• InChiKey: LMXUWARKUIELGT-UHFFFAOYSA-N

物化性质

• 熔点：
  333-335°C
• 沸点：
  566.95° C (Predicted)
• 密度：
  1.516±0.06 g/cm3(Predicted)
• 溶解度：
  二甲基亚砜（微溶）

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  108
• 氢给体数：
  2
• 氢受体数：
  6

安全信息

• 海关编码：
  2934100090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  -20°C 冰箱

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: N-(2-Chloro-6-methylphenyl)-2-[(6-chloro-2-methyl-4-pyrimidinyl)amino]-5-thiazolecarboxamide
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: N-(2-Chloro-6-methylphenyl)-2-[(6-chloro-2-methyl-4-pyrimidinyl)amino]-5-thiazolecarboxamide
302964-08-5
CAS number:

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Inhalation:
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
No data
Boiling point:
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C16H13Cl2N5OS
Molecular weight: 394.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride, sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

简介

N-(2-氯-6-甲基苯基)-2-[(6-氯-2-甲基-4-嘧啶基)氨基]-5-噻唑甲酰胺在常温常压下为黄色或浅黄色固体粉末状，属于多元杂环类化合物，可用作有机合成中间体。

溶解性

N-(2-氯-6-甲基苯基)-2-[(6-氯-2-甲基-4-嘧啶基)氨基]-5-噻唑甲酰胺在二甲基亚砜和甲醇中有一定的溶解性，在水中溶解性很差。

合成方法

N-(2-氯-6-甲基苯基)-2-[(6-氯-2-甲基-4-嘧啶基)氨基]-5-噻唑甲酰胺的合成是从其前体2-氨基-N-(2-氯-6-甲基苯基)噻唑-5-甲酰胺和4,6-二氯-2-甲基嘧啶出发，在碱性条件下，通过氨基对嘧啶环的芳香亲核取代反应得到目标产物。

环境危害

N-(2-氯-6-甲基苯基)-2-[(6-氯-2-甲基-4-嘧啶基)氨基]-5-噻唑甲酰胺作为一种含氮多元杂环有机化合物，对水环境具有较大危害。不可让未稀释或大量产品接触地下水、水道或污水系统。

反应信息

• 作为反应物：
  描述：

  N-(2-氯-6-甲基苯基)-2-[(6-氯-2-甲基-4-嘧啶基)氨基]-5-噻唑甲酰胺 在 N,N-二异丙基乙胺 、 三氟乙酸 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 48.03h， 生成 达沙替尼
  参考文献：
  名称：

  N-페닐-2-(피리미딘-4-일아미노)티아졸-5-카복사미드 유도체, 이의 약학적으로 허용 가능한 염 및 이를 유효성분으로 함유하는 미백 소재 조성물

  摘要：

  The composition of a whitening material containing an N-phenyl-2-(pyrimidin-4-ylamino)thiazole-5-carboxamide derivative as an active ingredient is provided. The whitening material composition provided in one aspect of the present invention has an excellent effect of inhibiting the promotion of melanin production in cells even with a small amount of use, so it can be effectively used as a skincare whitening cosmetic product, a product for the prevention, improvement, and treatment of melanin pigment excessive deposition disorders.

  公开号：

  KR20200104083A
• 作为产物：
  描述：

  N-(4-methoxybenzyl)-2-(6-chloro-2-methylpyrimidin-4-ylamino)-N-(2-chloro-6-methylphenyl)-1,3-thiazole-5-carboxamide 在 三氟甲磺酸 、 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 以99%的产率得到N-(2-氯-6-甲基苯基)-2-[(6-氯-2-甲基-4-嘧啶基)氨基]-5-噻唑甲酰胺
  参考文献：
  名称：

  2-氨基噻唑作为新型激酶抑制剂模板。结构活性关系研究对发现N-（2-氯-6-甲基苯基）-2-[[[6- [4-（2-羟乙基）-1-哌嗪基）]-2-甲基-4-嘧啶基的发现氨基]]-1,3-噻唑-5-羧酰胺（dasatinib，BMS-354825）作为有效的pan-Src激酶抑制剂。

  摘要：

  通过筛选我们的内部化合物集合，发现了2-氨基噻唑（1）作为一种新型Src家族激酶抑制剂模板。通过连续的结构-活性关系迭代进行的优化确定了类似物2（Dasatinib，BMS-354825）和12m是在生化和细胞分析中具有纳摩尔至亚纳摩尔浓度的pan-Src抑制剂。分子模型被用来构建推定的结合模型，以抑制这类化合物对Lck的抑制作用。该模型提出的关键氢键相互作用的框架与随后公布的与结构相似的Abl激酶结合的2的晶体结构一致。此类抑制剂的口服药效为12m，可在小鼠体内体外抑制促炎细胞因子IL-2（ED50约为5 mg / kg），并在急性小鼠炎症模型中降低TNF水平（LPS抑制90％） LPS给药前2小时以60 mg / kg口服给药时，TNF-α诱导的TNFα产生）。当每天两次以0.3和3 mg / kg口服给药时，在已确诊疾病的大鼠的慢性佐剂性关节炎模型中进一步证明了12m的口服功效。达沙

  DOI：

  10.1021/jm060727j
• 作为试剂：
  描述：

  2-氨基-N-(2-氯-6-甲基苯基)噻唑-5-甲酰胺 、 4,6-二氯-2-甲基嘧啶 、 sodium;hydride 在 N-(2-氯-6-甲基苯基)-2-[(6-氯-2-甲基-4-嘧啶基)氨基]-5-噻唑甲酰胺 作用下， 以 四氢呋喃 为溶剂， 以to obtain N-(2-chloro-6-methylphenyl)-2-[(6-chloro-2-methylpyrimidin-4-yl)amino]-1,3-thiazole-5-carboxamide (Formula 1d)的产率得到N-(2-氯-6-甲基苯基)-2-[(6-氯-2-甲基-4-嘧啶基)氨基]-5-噻唑甲酰胺
  参考文献：
  名称：

  Process for the preparation of dasatinib and its intermediates

  摘要：

  本发明涉及制备达沙替尼及其中间体的方法。

  公开号：

  US09365526B2

文献信息

• Design and Synthesis of Novel Dasatinib Analogues
  作者：G. Buchappa、K. Durgaprasad、B. Suneelkumar、P. Baby Rani、K. Ravi Babu、A.K.S. Bhujanga Rao、P. Aparna

  DOI：10.14233/ajchem.2016.19650

  日期：——

  Design, synthesis, characterization and in vitro biological assay of a series of novel carboxylic acid and amino acid analogs of dasatinib (1) as anticancer agents are reported. Some of the synthesized analogs were identified as potent Src/Abl kinase inhibitors with greater antiproliferative activity against K652 and T315I cancer cell lines. The synthetic process involves condensation of N-(2-chloro-6-methylphenyl)-2-[[6-[4(-1-pipearazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide with carboxylic acids in the presence of dicyclohexylcarbodiimide and oxyma in organic solvent medium. Compounds were characterized and tested for anticancer activity on leukemia cancer cell lines K562 and Baf3/T315. Analogues of lactic acid, mandalic acid, leucine and proline have shown promising antiproliferative activity compared to dasatinib.

  报道了以1型药物dasatinib为原型的系列新型羧酸和氨基酸类似物的设计、合成、表征以及体外生物学分析，作为抗癌药物。其中一些合成的类似物被鉴定为强效Src/Abl激酶抑制剂，对K652和T315I癌细胞系具有更高的抗增殖活性。合成过程涉及在有机溶剂介质中，以二环己基碳二亚胺和氧马酸作为催化剂，将N-(2-氯-6-甲基苯基)-2-[[6-[4(-1-哌拉嗪基]-2-甲基-4-嘧啶基]氨基]-5-噻唑羧酰胺与羧酸进行缩合反应。化合物经过表征并测试其对白血病癌细胞系K562和Baf3/T315的抗癌活性。与dasatinib相比，乳酸、苯乙酮酸、亮氨酸和脯氨酸类似物显示出有前景的抗增殖活性。
• [EN] BCR-ABL TYROSINE-KINASE LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME<br/>[FR] LIGANDS DE TYROSINE-KINASE BCR-ABL CAPABLES DE SE DIMÉRISER DANS UNE SOLUTION AQUEUSE, ET PROCÉDÉS D'UTILISATION DE CEUX-CI
  申请人：COFERON INC

  公开号：WO2015106292A1

  公开（公告）日：2015-07-16

  Described herein are monomers capable of forming a biologically useful multimer when in contact with one, two, three or more other monomers in an aqueous media. In one aspect, such monomers may be capable of binding to another monomer in an aqueous media (e.g. invivo) to form a multimer (e.g. a dimer). Contemplated monomers may include a ligand moiety, a linker element, and a connector element that joins the ligand moiety and the linker element. In an aqueous media, such contemplated monomers may join together via each linker element and may thus be capable of modulating one or more biomolecules substantially simultaneously, e.g., modulate two or more binding sites on a Bcr-Abl tyrosine kinase.

  本文描述了一种单体，当与水性介质中的另一个、两个、三个或更多其他单体接触时，能够形成生物学上有用的多聚体。在一个方面，这种单体可能能够在水性介质（例如体内）中与另一个单体结合以形成多聚体（例如二聚体）。考虑到的单体可能包括配体基团、连接元素和连接配体基团与连接元素的连接元素。在水性介质中，这些考虑到的单体可以通过每个连接元素结合在一起，因此可以同时调节一个或多个生物分子，例如，调节Bcr-Abl酪氨酸激酶上的两个或更多结合位点。
• Discovery of SIAIS178 as an Effective BCR-ABL Degrader by Recruiting Von Hippel–Lindau (VHL) E3 Ubiquitin Ligase
  作者：Quanju Zhao、Chaowei Ren、Linyi Liu、Jinju Chen、Yubao Shao、Ning Sun、Renhong Sun、Ying Kong、Xinyu Ding、Xianfang Zhang、Youwei Xu、Bei Yang、Qianqian Yin、Xiaobao Yang、Biao Jiang

  DOI：10.1021/acs.jmedchem.9b01264

  日期：2019.10.24

  chimeric (PROTAC) small molecules targeting BCR-ABL which connect dasatinib and VHL E3 ubiquitin ligase ligand by extensive optimization of linkers. Our efforts have yielded SIAIS178 (19), which induces proper interaction between BCR-ABL and VHL ligase leading to effective degradation of BCR-ABL protein, achieves significant growth inhibition of BCR-ABL+ leukemic cells in vitro, and induces substantial

  致癌融合蛋白BCR-ABL是慢性粒细胞白血病（CML）中白血病发生的驱动力。尽管通过应用针对BCR-ABL的酪氨酸激酶抑制剂（TKI）在CML治疗方面取得了巨大进展，但长期给药和临床耐药仍是一个问题。在这里，我们描述了通过广泛优化接头来连接达沙替尼和VHL E3泛素连接酶配体的靶向BCR-ABL的靶向BCR-ABL的新型蛋白水解靶向嵌合（PROTAC）小分子的设计，合成和评估。我们的努力产生了SIAIS178（19），该SIAIS178诱导BCR-ABL和VHL连接酶之间适当的相互作用，导致BCR-ABL蛋白有效降解，并实现对BCR-ABL +的显着生长抑制。体外白血病细胞，并在体内诱导针对K562异种移植肿瘤的实质性肿瘤消退。此外，SIAIS178还降解了一些临床相关的赋予耐药性的突变。我们的数据表明，SIAIS178作为有效的BCR-ABL降解剂值得对BCR-ABL +白血病的治疗进行广泛的进一步研究。
• [EN] PHOTOAFFINITY PROBES<br/>[FR] SONDES DE PHOTOAFFINITÉ
  申请人：PROMEGA CORP

  公开号：WO2020191339A1

  公开（公告）日：2020-09-24

  Provided herein are compositions and methods for photoaffinity labeling of molecular targets. In particular, probes that specifically interact with cellular targets based on their affinity and are then covalently linked to the cellular target via a photoreactive group (PRG) on the probe.

  本文件提供了用于光亲和标记分子靶点的组合物和方法。特别是，基于它们的亲和力与细胞靶点特异性相互作用的探针，然后通过探针上的光反应组（PRG）与细胞靶点共价连接。
• [EN] BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE<br/>[FR] AGENTS DE DÉGRADATION BIFONCTIONNELS ET LEURS MÉTHODES D'UTILISATION
  申请人：NOVARTIS AG

  公开号：WO2021053495A1

  公开（公告）日：2021-03-25

  Described herein are bifunctional degrader compounds, their various targets, their preparation, pharmaceutical compositions comprising them, and their use in the treatment of conditions, diseases, and disorders mediated by various target proteins.

  本发明描述了双功能降解剂化合物、它们的多种靶点、它们的制备方法、包含它们的药物组合物，以及它们在治疗由各种靶点蛋白质介导的条件、疾病和失调症中的用途。